Previous 10 | Next 10 |
Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort PR Newswire The preliminary findings reported include patients that showed improvement in atopic dermatitis symptoms and severi...
Hoth Therapeutics (NASDAQ:HOTH) said it is adding a new asset to its pipeline, HT-TBI. The company said HT-TBI is being developed as a point-of-care therapy for treating secondary brain injury (such as brain edema and inflammation) resulting from ischemic stroke and traumatic brain injury (TB...
Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury PR Newswire HT-TBI is a novel, point-of-care drug-device combination product under development for acute treatment of secondary brain injury resulting from ischemic stroke and ...
Hoth Therapeutics, Inc. Announces Closing of $7.0 Million Underwritten Public Offering Priced At-The-Market PR Newswire NEW YORK , April 14, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today an...
Gainers: Lixte Biotechnology Holdings (LIXT) +205%. PolarityTE (PTE) +96%. Biodesix (BDSX) +29%. MiNK Therapeutics (INKT) +27%. Enservco (ENSV) +25%. Actinium Pharmaceuticals (ATNM) +21%. Compass Therapeutics (CMPX) +21%. Sunshine Biopharma (SBFM) +22%. Singularity Future Technology (SGLY) +2...
Gainers: Lixte Biotechnology LIXT +263%. BioCardia BCDA +29%. Biodesix BDSX +27%. Aeglea BioTherapeutics AGLE +16%. Actinium Pharmaceuticals ATNM +14%. Losers: Hoth Therapeutics HOTH -30%. Altamira Therapeutics CYTO -29%. Myovant Sciences (MYO...
Hoth Therapeutics Announces Acceptance to Present HT-ALZ Proof-of-Concept Alzheimer's Disease Data at the 2022 Alzheimer's Association International Conference PR Newswire Dr. Yuede will present the preclinical Alzheimer's disease mouse model data for exploring HT-ALZ ...
Hoth Therapeutics (NASDAQ:HOTH) is down 12.4% after hours after the firm has priced its underwritten public offering of 8,235,294 shares of common stock at $0.85/share for aggregate gross proceeds of ~$7.0M. Underwriters green shoe options is for another ~1.24M shares of common stoc...
Hoth Therapeutics, Inc. Announces Pricing of $7.0 Million Underwritten Public Offering Priced At-The-Market PR Newswire NEW YORK , April 11, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today an...
The development-stage pharmaceutical company Hoth Therapeutics (NASDAQ:HOTH) followed up its impressive preclinical data for its investigational cancer therapy, HT-KIT with the start of an underwritten public offering of common stock on Monday. Following the announcement, the shares of the Ne...
News, Short Squeeze, Breakout and More Instantly...
Hoth Therapeutics Inc. Company Name:
HOTH Stock Symbol:
NASDAQ Market:
Hoth Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment PR Newswire Treatment of pre-clinical subjects showed cognitive benefits that suggest HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitiv...